iBio公司近日公布了其候选药物IBIO-610在肥胖非人灵长类动物模型中取得的临床前体成分数据。这项研究聚焦于IBIO-610作为一种潜在首创疗法的效果,该疗法旨在实现脂肪选择性减重,标志着公司在代谢疾病治疗领域的重要进展。
iBio公司近日公布了其候选药物IBIO-610在肥胖非人灵长类动物模型中取得的临床前体成分数据。这项研究聚焦于IBIO-610作为一种潜在首创疗法的效果,该疗法旨在实现脂肪选择性减重,标志着公司在代谢疾病治疗领域的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.